Latest Oncology News

FDA Clears IND for BEAM-201 in Relapsed/Refractory T-ALL/T-LL

December 05, 2022

The clinical hold for the development of BEAM-201 has been lifted, allowing investigators to assess the agent in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/ T-cell lymphoblastic lymphoma.

BI 1810631 Shows Early Antitumor Activity in NSCLC

December 04, 2022

Although HER2 mutations present in many solid tumors, lung cancer is of particular interest because a significant number of mutations are found in the tyrosine kinase domain of the gene. Of those, about 90% take the form of insertions or deletions, according study findings.

Updates Results Support Repotrectinib in ROS1+ NSCLC

December 03, 2022

Updated findings from the TRIDENT-1 suggest that repotrectinib could represent a potential new treatment option for patients with ROS1- positive advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.